🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies

Recruitingn/aAges any - anyAllARCE Therapeutics, Inc.
NCT06906380 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study will evaluate the long-term safety of ARD103 cellular therapies

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * The participant has R/R AML or MDS and has previously received ARD103 CAR-T cell therapies in the parent study. * The participant is able to understand and comply with protocol-required study procedures and has provided a written informed consent document. Exclusion Criteria: * There are no specific exclusion criteria for this study
💊

What it tests

  • Non interventional study
📍

Where

3 sites
Novant Health Cancer Institute
Charlotte, United States
Novant Health Cancer Institute
Winston-Salem, United States
MD Anderson Cancer Center
Houston, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy